Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1693-1698

  Wahba, Hanan Ahmed ^a   El Hadaad, Hend Ahmed ^a   Abd Ellatif, Ehab Atef ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Capecitabine; Locally advanced esophegeal cancer; Neoadjuvant chemoradiotherapy; Oxaliplatin

Indexed keywords

CAPECITABINE; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DERMATITIS; DIARRHEA; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; MALE; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; YOUNG ADULT;

EID: 84872811742     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0001-2     Document Type: Article

References (29)

1. Lerut T, Coosemans W, Decker G, De Leyn P, Nafteux P, Van Raemdonck D. Cancer of the esophagus and gastroesophegeal junction: potentially curative therapies. Surg Oncol. 2001; 10:113-22.
2. Falk J, Carstens H, Lundell L, Albertsson M. Incidence of carcinoma of the oesophegus and gastric Cardia-Changes over time and geographical differences. Acta Oncol. 2007;46:1070-4.
3. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in oesophegeal cancer: lessons from more than 1, 000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234(3):360-7. discussion 368-9.
4. Piessen G, Mariette C, Triboulet JP. Cervical and upper third thoracic oesophegeal carcinoma: a single pathological entity? Ann Chir. 2005;130(2):86-91.
5. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy and surgery compared with surgery alone for oesophegeal cancer. CALGB 9781. J Clin Oncol. 2008;26(7):1086-92.
6. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, et al. Proposed revision of the oesophegeal cancer staging system to accommodate pathologic response (PP) following pre-operative chemoradiation. Ann Surg. 2005;241: 810-20.
7. Brücher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in oesophegeal squamous cell carcinoma. Cancer. 2006;106:2119-27.
8. Byfield JE. Combined modality infusional chemotherapy with radiation. In: Lokich JJ, editor. Cancer Chemotherapy by Infusion. 2nd ed. Chigaco, IL: Percepta Press; 1990. p. 521-51.
9. AL-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy vs radiotherapy alone in patients with oesophegeal cancer: an intergroup study. J Clin Oncol. 1997;15:277-84.
10. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, et al. Oxaliplatin in combination with protracted infusion fluorouracil and radiation: report of a clinical trial for patients with oesophegeal cancer. J Clin Oncol. 2002;20: 2844-50.
11. Magné N, Fischel JL, Formento P, Etienne MC, Dubreuil A, Marcié S, et al. Oxaliplatin, 5-fluorouracil and ionizing radiation. Importance of the sequence and influence of the p53 status. Oncology. 2003;64:280-7.
12. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291-7.
13. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5:2948-53.
14. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbonate in human cancer xenografts. Biochem Pharmacol. 1998;55:1091-7.
15. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al. Phase II study of capecitabine and oxaliplatin in first and second line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002;20:1759-66.
16. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (Capecitabine plus oxaliplatin : active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084-91.
17. World Health Organization. WHO handbook for reporting results of cancer treatment: WHO offset publication no 48. Switzerland: World Health Organization; 1979.
18. Cox JD, Stetz J, Aja TF. Toxicity criteria of the radiation therapy oncology group (RTOG). Int J Radiat Oncol Biol Phys. 1995;31:1341-6.
19. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CT CAE V. 3.0 development of comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-81.
20. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-30.
21. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB Jr, Ajani JA, et al. Treatment outcomes of resected oesophegeal cancer. Ann Surg. 2002;236:376-84. discussion. 384-385.
22. Keighley MRB. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther. 2003;18(suppl. 3):7-30.
23. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localised carcinoma of the oesophegus (Cochrane Review). in The Cochrane Library, Issue 1. Oxford, Update Softwer; 2003.
24. Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, et al. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br JCancer. 2008; 99(7):1020-6.
25. van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der Gaast A. First line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophegeal cancer: a phase II study. Br J Cancer. 2007;96:1348-52.
26. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593-8.
27. Ishikura S, Nihei K, Ohtsu A, et al. Long term toxicities after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic oesophegus. J Clin Oncol. 2002;21:2697-702.
28. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the oesophegus: a Japan Esophegeal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). J pn J Clin Oncol. 2004;34:615-9.
29. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the oesophegus: FFCD 9102. J Clin Oncol. 2007;25:1160-8.